Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

C0410000

Canrenone

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(17α)-17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid γ-lactone, NSC 261713

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H28O3
CAS Number:
976-71-6
Molecular Weight:
340.46
MDL number:
MFCD00071735
UNSPSC Code:
41116107
PubChem Substance ID:
329774785
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

canrenone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

C[C@@]12C(C=C[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]45OC(CC5)=O)=CC(CC1)=O

InChI

1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1

InChI key

UJVLDDZCTMKXJK-WNHSNXHDSA-N

Gene Information

human ... NR3C2(4306)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Canrenone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazardEnvironment
GHS08,GHS09

Signal Word

Warning

Hazard Statements

H351,H411

Precautionary Statements

P201 - P273 - P308 + P313

Hazard Classifications

Aquatic Chronic 2 - Carc. 2 Oral

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniela Iuliana Sora et al.
Journal of pharmaceutical and biomedical analysis, 52(5), 734-740 (2010-03-24)
A new sensitive HPLC/MS/MS method for simultaneous determination of furosemide, spironolactone and canrenone in human plasma samples is presented. Electrospray ionization source (ESI) has been used. The tandem MS detection was performed under MRM conditions, in the negative ion mode
Alessandro Mussa et al.
Endocrine journal, 59(6), 497-502 (2012-03-27)
Familial hyperaldosteronism (FH) encompasses 3 types of autosomal dominant hyperaldosteronisms leading to inheritable hypertension. FH type II (FH-II), undistinguishable from sporadic hyperaldosteronism, represents the most frequent cause of inheritable hypertension and is believed to only manifest in adults. FH-III is
Haijuan Dong et al.
Journal of mass spectrometry : JMS, 41(4), 477-486 (2006-03-17)
A sensitive and specific liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry (LC-APCI-MS) method for the simultaneous determination of spironolactone and its active metabolite canrenone in human plasma has been developed and validated. After the addition of estazolam as the internal standard
Alessandro Boccanelli et al.
European journal of heart failure, 11(1), 68-76 (2009-01-17)
To test whether canrenone, an aldosterone receptor antagonist, improves left ventricular (LV) remodelling in NYHA class II heart failure (HF). Aldosterone receptor antagonists improve outcome in severe HF, but no information is available in NYHA class II. AREA IN-CHF is
John G F Cleland et al.
European journal of heart failure, 9(8), 850-853 (2007-07-24)
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at Heart Rhythm 2007 organised by the Heart Rhythm Society which was held in Denver, USA and Heart Failure 2007
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service